Active Ingredient(s): Miglustat
FDA Approved: * July 31, 2003
Pharm Company: * ACTELION PHARMS
Category: Enzymes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zavesca Overview

Miglustat, sold under the brand name Zavesca, is a medication used to treat type I Gaucher disease (GD1). It was developed by Oxford GlycoSciences and is marketed by Actelion. Miglustat has been approved in the EU, Japan, and Canada for treating progressive neurological complications in people with Niemann–Pick disease, type C (NPC). It was approved for medical use in the European Union in November 2002,[4][5] and for medical use in the United States in J...

Read more Zavesca Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Zavesca Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zavesca: (1 result)

Sorted by National Drug Code
  • 66215-201 Zavesca 100 mg Oral Capsule by Actelion Pharmaceuticals Us, Inc.

Other drugs which contain Miglustat or a similar ingredient: (1 result)

Related Zavesca Topics:

Treatment for Type 1 Gaucher ## Zavesca contains the active ingredient Miglustat. Common side effects may include: nause... 1 reply